



Corcept Therapeutics Announces Presentations at the American Association of Clinical Endocrinologists 27th Annual Congress

May 16, 2018

MENLO PARK, Calif. (May 16, 2018) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced poster presentations at the 27th Annual Congress of the American Association of Clinical Endocrinologists (AACE) in Boston, Massachusetts (May 16 – 20). The presentations focus on the role of Koriym® in treating patients with hypercortisolism and the development of Corcept's next-generation selective cortisol modulator, relacorilant.

"We are pleased AACE accepted our late-breaking poster describing the positive interim results of our Phase 2 trial of relacorilant to treat patients with Cushing's syndrome," said Joseph K. Belanoff, MD, Corcept's Chief Executive Officer. "Relacorilant's potent effect at low doses surprised us. We look forward to sharing our results with the endocrine community. The posters presenting clinical observations with Koriym are also important. For many patients, cortisol modulation is a powerful treatment option."

Corcept is also sponsoring an oral presentation by Hanford Yau, M.D., "Re-examining the Diagnosis and Management of Hypercortisolism."

Thursday, May 17	
Oral Presentation (1-1:45 pm, Product Theater A) <i>Re-examining the Diagnosis and Management of Hypercortisolism</i>	<ul style="list-style-type: none"> H. Yau, M.D.
Friday, May 18	
Poster #259 <i>Mifepristone Decreases the use of Concentrated U-500 Insulin in Patients with Endogenous Hypercortisolism who have Type 2 Diabetes Mellitus</i>	<ul style="list-style-type: none"> J. Mathews, M.D., FACE; J. Smith, Ph.D.
Saturday, May 19	
Poster #106 <i>Marked Improvement in Metabolic Parameters in a Patient with ACTH-Independent Hypercortisolism While on Mifepristone</i>	<ul style="list-style-type: none"> R. Ray, CRNP; R. Bunta, MBA; P. Dauphin, M.D.
Saturday, May 19	
Poster #803 <i>Phenotypic and Metabolic Improvements in a Patient with Equivocal Findings of Hypercortisolism Treated with Mifepristone: Photographic and Radiographic Evidence</i>	<ul style="list-style-type: none"> M. Thomas, M.D., Ph.D.; J. Smith, Ph.D.
Late-Breaking Poster #1219 <i>Open-Label Phase 2 Study to Assess Safety and Efficacy of Relacorilant (CORT125134), a Selective Cortisol Modulator, in the Treatment of Endogenous Hypercortisolism</i>	<ul style="list-style-type: none"> I. Bancos, M.D., M. Wierman, M.D.; J. Silverstein, M.D.; N. Agrawal, M.D.; F. Celi, M.D., MHSc.; M. Gordon, M.D.; Atil Y. Kargi, M.D.; S. Lerman, M.D.; C. Mariash, M.D., A. Moraitis, M.D.

About Koriym®

Koriym inhibits the effects of excess cortisol in patients with hypercortisolism by modulating activity at the glucocorticoid receptor, one of the two receptors to which cortisol binds. Koriym was the first FDA- approved treatment for patients with Cushing's syndrome and the FDA has designated it as an Orphan Drug for that indication.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept has a large portfolio of proprietary compounds, including relacorilant, that modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the use of cortisol modulators in the treatment of a wide variety of serious disorders, including Cushing's syndrome. It also holds composition of matter patents covering its selective cortisol modulators.

CONTACT:

Charles Robb
 Chief Financial Officer
 Corcept Therapeutics
 650-688-8783
corb@corcept.com
www.corcept.com